Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
H + -K + -ATPase inhibitor. It blocks the final stage of the secretion of hydrochloric acid, reduces the level of basal and stimulated (regardless of the type of stimulus) secretion of hydrochloric acid in the stomach. In duodenal ulcer associated with Helicobacter pylori, this reduction in gastric secretion increases the sensitivity of microorganism to antibiotics. Pantoprazole has its own antimicrobial activity against Helicobacter pylori.
INDICATIONS
Peptic ulcer of the stomach or duodenum in the phase of exacerbation, Zollinger-Ellison syndrome, Helicobacter pylori eradication (in combination with antibacterial therapy), reflux esophagitis.
DOSING MODE
The average therapeutic dose is 40 mg / day. The maximum daily dose is 80 mg. The duration of the course of therapy is set depending on the indications, but it should not exceed 8 weeks.
SIDE EFFECT
From the digestive system: diarrhea; rarely - nausea, pain in the upper abdomen, flatulence.
From the side of the central nervous system: headache; rarely - weakness, dizziness; in isolated cases - the initial manifestations of depressive conditions, visual impairment.
Dermatological reactions: rarely - rash, itching.
Other: weakness, dizziness; in single cases - swelling, fever.
CONTRAINDICATIONS
Dyspepsia of neurotic genesis, malignant diseases of the digestive tract, increased sensitivity to pantoprazole.
PREGNANCY AND LACTATION
If it is necessary to use pantoprazole during pregnancy, it is necessary to evaluate the prospective benefit to the mother and the potential risk to the fetus.
If it is necessary to use during lactation, the question of stopping breastfeeding should be resolved.
In experimental studies , it has been established that pantoprazole is excreted in breast milk.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS
When used in patients with impaired liver function, the activity of liver enzymes in the blood plasma should be regularly monitored and when pantoprazole is removed, pantoprazole should be withdrawn.
SPECIAL INSTRUCTIONS
Before the start of therapy, the possibility of a malignant neoplasm in the stomach and esophagus should be excluded, since the use of pantoprazole reduces the severity of symptoms and may delay the establishment of a correct diagnosis. The diagnosis of reflux esophagitis requires mandatory endoscopic confirmation.
When used in patients with impaired liver function, the activity of liver enzymes in the blood plasma should be regularly monitored and when pantoprazole is removed, pantoprazole should be withdrawn.
DRUG INTERACTION
With the simultaneous use of pantoprazole can change the absorption of drugs, the absorption of which depends on the pH of the gastric contents (ketoconazole).
Due to the fact that pantoprazole is metabolized in the liver by the enzymatic system of cytochrome P450, it is impossible to exclude the possibility of drug interaction with drugs metabolized by the same enzyme system.
